Novartis Cosentyx meets primary endpoint in patients with axial spondyloarthritis

Novartis Cosentyx is backed by clinical evidence, including 5-year data across three indications of psoriasis, PsA and AS as well as data from real-world evidence.

Basel: Novartis recently announced positive new data from the PREVENT trial evaluating the efficacy and safety of Cosentyx (secukinumab) in patients with nr-axSpA (non-radiographic axial spondyloarthritis).

Cosentyx is the first and only fully-human biologic that directly inhibits interleukin-17A (IL-17A), a cornerstone cytokine involved in the inflammation and development of psoriatic arthritis (PsA), psoriasis (PsO), and ankylosing spondylitis (AS).

Cosentyx is backed by clinical evidence, including 5-year data across three indications of psoriasis, PsA and AS as well as data from real-world evidence. These data strengthen the unique position of Cosentyx as a rapid and long-lasting comprehensive treatment across axial spondyloarthritis, psoriatic arthritis and psoriatic disease, with more than 250,000 patients treated worldwide with Cosentyx since launch.

PREVENT is an ongoing two-year randomized, double-blind, placebo-controlled Phase III study (with a two-year extension phase) to investigate the efficacy and safety of Cosentyx, in patients with active nr-axSpA.

The ongoing Phase III trial met its primary endpoint of ASAS40 at Week 16, showing a significant and clinically meaningful reduction in disease activity for patients treated with Cosentyx versus placebo. The trial demonstrated a favourable safety profile consistent with previous clinical trials.

“These study results for Cosentyx build on our long-standing experience in ankylosing spondylitis and are a step toward a new treatment option that could allow patients to realize relief much earlier in axial spondyloarthritis,” said John Tsai, M.D., Head of Global Drug Development and Chief Medical Officer for Novartis.

“If approved, this would be the fourth indication for Cosentyx.”

Detailed data is planned to be presented at a future scientific congress. These data add to the existing evidence supporting Cosentyx as a rapid and long-lasting comprehensive treatment, backed by evidence from over 100 studies, across axial spondyloarthritis, psoriatic arthritis and psoriatic disease, with over 250,000 patients treated worldwide.

Read Also: Jubilant Life appoints Novartis Syed Kazmi as President, CEO of its new biotech startup